Eupraxia Pharmaceuticals Inc.

NasdaqCM:EPRX Stock Report

Market Cap: US$438.2m

Eupraxia Pharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

James Helliwell

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage9.46%
CEO tenure14yrs
CEO ownership1.6%
Management average tenureless than a year
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has James Helliwell's remuneration changed compared to Eupraxia Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$47m

Dec 31 2025US$5mUS$429k

-US$41m

Sep 30 2025n/an/a

-US$32m

Jun 30 2025n/an/a

-US$31m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$1mUS$394k

-US$26m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$517kUS$363k

-US$28m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$953kUS$325k

-US$18m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$1mUS$297k

-US$19m

Compensation vs Market: James's total compensation ($USD4.54M) is above average for companies of similar size in the US market ($USD2.47M).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James Helliwell (52 yo)

14yrs
Tenure
US$4,535,622
Compensation

Dr. James A. Helliwell, M.D., FRCPC serves as the Chief Executive Officer at Eupraxia Pharmaceuticals Inc. since July 2012 and served as its President until May 3, 2021. Dr. Helliwell serves as a Clinical...

Leadership Team

NamePositionTenureCompensationOwnership
James Helliwell
CEO & Director14yrsUS$4.54m1.61%
$ 7.1m
Alexander Rothwell
Chief Financial Officer1.4yrsUS$5.44m1.16%
$ 5.1m
Amanda Malone
Chief Scientific Officer & COO13.8yrsUS$2.30m0.071%
$ 310.9k
Paul Brennan
Chief Corporate Development Officerless than a yearUS$985.02k0.074%
$ 325.3k
Wajida Leclerc
Executive Vice President Corporate Services & Peopleless than a yearno datano data
Alex Therien
Executive VP of R&Dno datano datano data
Jeymi Tambiah
Chief Medical Officerless than a yearno datano data
1.0yrs
Average Tenure
54.5yo
Average Age

Experienced Management: EPRX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
James Helliwell
CEO & Director14yrsUS$4.54m1.61%
$ 7.1m
Simon Pimstone
Independent Chairman13.5yrsUS$404.64k0.075%
$ 326.5k
Richard Glickman
Independent Director5.3yrsUS$278.52k0.029%
$ 126.5k
Joseph Freedman
Independent Director1.8yrsUS$264.21k3.89%
$ 17.1m
John Montalbano
Independent Director13.5yrsUS$339.65k2.35%
$ 10.3m
Amy Pott
Directorless than a yearno datano data
Evan Dellon
Chairman of Clinical Advisory Board2.2yrsno datano data
Donna Griebel
Member of Clinical Advisory Board2.2yrsno datano data
Albert Bredenoord
Member of Clinical Advisory Board2.2yrsno datano data
Roos Pouw
Member of Clinical Advisory Board2.2yrsno datano data
Stephen Attwood
Member of Clinical Advisory Board2.2yrsno datano data
Nirmala Gonsalves
Member of Clinical Advisory Board2.2yrsno datano data
2.2yrs
Average Tenure
57yo
Average Age

Experienced Board: EPRX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 22:53
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eupraxia Pharmaceuticals Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.